14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026
ZKH vs ZJYL: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 19, 2026, JIN MEDICAL INTERNATIONAL LTD. (ZJYL) is the stronger overall head-to-head candidate over ZKH Group Limited (ZKH) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). ZKH carries a Unified Composite Score of 50.3/100 (HOLD) at $1.47 (3.3x Forward P/E, -0.8% operating margin), whereas ZJYL carries 33.4/100 (SELL) at $3.34 (N/M Forward P/E, 2.1% operating margin).
Composite vs. Pillar Nuance: While ZKH currently prints a higher short-term Unified Composite Score (50.3/100 HOLD vs. ZJYL 33.4/100 SELL), ZJYL captures the overall institutional head-to-head verdict (6–4 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (2.1% vs. -0.8% operating margin) and revenue trajectory (-9.7% vs. +12.8% YoY).
Technical & Structure Timing Caution: ZKH is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 40.4); meanwhile ZJYL trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 54.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ZKH vs ZJYL. Trailing 12-month operating profitability (ZKH -0.8% vs ZJYL 2.1%) and valuation multiples (ZKH 3.3x vs ZJYL N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Medical Instruments & Supplies value chain with $534.9M market capitalization and 2.1% operating margin.
OpEx & R&D Reinvestment29.2% of Rev ($148M)
90D Engineering Disclosures0 Published
Investor FAQ ZKH vs ZJYL Key Questions & Quantitative Answers
As of Nov 19, 2026, JIN MEDICAL INTERNATIONAL LTD. (ZJYL) is the stronger overall head-to-head candidate over ZKH Group Limited (ZKH) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). ZKH carries a Unified Composite Score of 50.3/100 (HOLD) at $1.47 (3.3x Forward P/E, -0.8% operating margin), whereas ZJYL carries 33.4/100 (SELL) at $3.34 (N/M Forward P/E, 2.1% operating margin). Composite vs. Pillar Nuance: While ZKH currently prints a higher short-term Unified Composite Score (50.3/100 HOLD vs. ZJYL 33.4/100 SELL), ZJYL captures the overall institutional head-to-head verdict (6–4 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (2.1% vs. -0.8% operating margin) and revenue trajectory (-9.7% vs. +12.8% YoY). Technical & Structure Timing Caution: ZKH is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 40.4); meanwhile ZJYL trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 54.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
ZKH leads the Growth & Scale pillar: ZKH posts +12.8% YoY revenue growth and +0.0% YoY earnings growth on $9.44B TTM revenue (16.6% gross margin, -0.8% operating margin), compared with ZJYL at -9.7% YoY revenue growth and -32.0% YoY earnings growth on $508M TTM revenue (31.3% gross margin, 2.1% operating margin). On trailing 12-month operating scale, ZKH generates $9.44B in USD-normalized revenue versus $508M for ZJYL. In operating R&D and SG&A reinvestment, ZKH deploys 17.4% of Rev ($1.64B) (0 90-day corporate R&D disclosures) versus 29.2% of Rev ($148M) (0 disclosures) for ZJYL.
ZJYL screens cheaper on headline valuation multiples. ZKH trades at 3.3x Forward P/E, 28.2x Trailing P/E, N/M PEG, and N/M EV/Revenue (-0.4% EBITDA margin), whereas ZJYL trades at N/M Forward P/E, 17.7x Trailing P/E, N/M PEG, and 1.1x EV/Revenue (3.3% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ZKH (-0.1% ROE) versus ZJYL (4.0% ROE) capital efficiency.
In options market volatility and institutional positioning, ZKH carries N/A implied volatility (N/A, Unclassified), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.20β · 94% Vol realized risk). By comparison, ZJYL carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (13.88β · 178% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.